According to public information, Li Weidong was the Vice General Manager and Operation Head of Westvac Biopharma before joining GSK.

Li Weidong has 25 years of experience in the pharmaceuticals industry, including over 14 years in the vaccine field, and has worked for multinational pharmaceutical companies such as Xi'an Janssen, Sanofi Pasteur, and Pfizer., during his time at Pfizer, he served as the Director of Market Access for Pfizer China Vaccines. He left Pfizer in 2021 and joined WestVac Biopharma as the Vice General Manager and Operations...Camp Leader.

Feng Bixia, the former head of GSK China's vaccine business, joined GSK in September 2019 as the General Manager for Hong Kong and Macau in GSK's Greater China and Intercontinental Region. In June 2021, Feng Bixia was appointed as the head of GSK China's vaccine business. On August 9 this year, Feng Bixia officially left GSK.

Since the beginning of this year, GlaxoSmithKline has made significant adjustments to its organizational structure and business segments. Effective January 1, GSK China will reorganize its operations.Three Core Business Departments: Specialty Medicines, Vaccines, and Respiratory。

Under the new organizational structure, the original product lines have also undergone changes in affiliation, such as,Nucala (Mepolizumab) from the original specialty drugs business is integrated into the new respiratory business unit., the other interleukin receptor antagonist Depemokimab, which will be introduced in the future, has also been placed in the new respiratory business unit.The original hepatitis and HIV products have been integrated into the new specialty medicines business unit.

GSK's 2024 Half-Year Report Shows Q2 Sales of £7.884 Billion ($10.09 Billion), Up 13% Year-on-Year (at Constant Exchange Rates); H1 Total Revenue Reaches £15.247 Billion ($19.516 Billion), Up 12% Year-on-Year.

Among them,Vaccine Sales Increase by 1%, removing the impact of COVID-19 products, growth increased by 3%.Sales of specialty medicines grew 22%, sales of HIV products increased by 13%, oncology product sales more than doubled to £400 million ($512 million), and sales of generic medicines rose 12%.

The vaccine business has shown strong growth momentum. Excluding the impact of COVID-19 products,GSK's vaccine business sales increased by 3% year-on-year in the second quarter of 2024, reaching £1.999 billion ($2.559 billion).。

In the first half of the year, vaccine sales achieved a 12% year-on-year increase, reaching £4.276 billion ($5.473 billion), accounting for 28% of the company's total revenue.This growth was mainly driven by the strong sales of meningococcal vaccine (meningitis), shingles vaccine Shingrix (outside the United States), and respiratory syncytial virus (RSV) vaccine Arexvy.

Based on its outstanding growth performance, GSK has raised its full-year performance forecast from 5%-7% to 7%-9%.

—END—

Highlights:

Another Innovative Pharmaceutical Company Goes Public, Stock Price Surges Over 28% at Its Peak

Junshi Biosciences Narrows Losses, Are Chinese Innovative Drug Companies Reaching a Profit Turning Point?

List of Listed Traditional Chinese Medicine Enterprises: 17 Achieve Double Growth, Six Giants with Net Profit Over 1 Billion

World's First! China-Made "Million-Dollar Cancer Drug" Approved, $1 Billion in Sales Expected Within the Year